Loading...
OTCM
SHIEF
Market cap79mUSD
Oct 13, Last price  
0.07USD
Name

Shield Therapeutics PLC

Chart & performance

D1W1MN
OTCM:SHIEF chart
P/E
—
P/S
1.16
EPS
—
Vol. 1Y
—
Shs. 5Y
48.83%
Rev. 5Y
37.33%
Div Yld LY
—
Div Yld TTM
—
Revenues
51m
+61.05%
0000304,000637,00011,881,000719,00010,387,0001,519,0005,499,00016,539,45831,508,04150,743,741
Net income
-18m
L-32.27%
-5,053,881-6,809,215-12,905,000-23,627,000-15,016,000-19,588,000-1,794,000-8,800,000-2,630,000-19,336,000-40,444,000-33,293,000-26,614,405-18,025,406
CFO
-9m
L+0.48%
-4,650,7910-3,341,000-4,183,000-10,256,000-16,151,000166,000-4,066,000-1,400,000-16,738,000-18,247,000-46,927,317-8,766,049-8,807,996

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Key people

Hans Hasler
Non-Executive Independent Chairman of the Board · since 2020
Santosh Shanbhag
Chief Financial Officer · since 2024
David Childs
Vice President - Manufacturing and Strategic Alliances · since 2023
Jackie Mitchell
Vice President - Quality, Clinical and Regulatory Affairs · since 2024
Andy Hurley
Chief Commercial Officer · since 2023
Lucy Huntington-Bailey
Chief Compliance Officer, General Counsel, Company Secretary · since 2024
Anders Lundstrom
Chief Executive Officer, Director · since 2025
Christian Schweiger
Non-Executive Director · since 2020
Rudolf Widmann
Non-Executive Director · since 2024
Fabiana Lacerca-Allen
Non-Executive Independent Director · since 2021
Peter Llewellyn-Davies
Non-Executive Independent Vice Chairman of the Board · since 2024
URL
https://www.shieldtherapeutics.com/
IPO date
Feb 26, 2016
Employees
27
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR
BALTIC BUSINESS QUARTER, GATESHEAD QUAYS
GATESHEAD, GAT NE8 3DF
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT